is accompanied by
We compared 200 U intradetrusor botulinum toxin A vs placebo in women with refractory idiopathic urge incontinence.
Materials and Methods:
This institutional review board approved, multicenter registered trial randomized women with refractory urge incontinence, detrusor overactivity incontinence and 6 or greater urge incontinence episodes in 3 days to botulinum toxin A or placebo at a 2:1 ratio. Refractory was defined as inadequate symptom control after 2 or more attempts at pharmacotherapy and 1 or more other first line therapies for detrusor overactivity incontinence. The primary outcome measure was time to failure, as evidenced by a Patient Global Impression of Improvement score of 4 or greater at least 2 months after injection, or changes in treatment (initiation or increase) at any time after injection. Safety data, including increased post-void residual volume, defined as more than 200 ml irrespective of symptoms, was obtained at specified time points.
Approximately 60% of the women who received botulinum toxin A had a clinical response based on the Patient Global Impression of Improvement. The median duration of their responses was 373 days, significantly longer than the 62 days or less for placebo (p <0.0001). In the botulinum toxin A group increased post-void residual urine (12 of 28 women or 43%) and urinary tract infection in those with increased post-void residual urine (9 of 12 or 75%) exceeded expected ranges. Further injections were stopped after 43 patients were randomized, including 28 to botulinum toxin A and 15 to placebo.
Local injection of 200 U botulinum toxin A was an effective and durable treatment for refractory overactive bladder. However, a transient post-void residual urine increase was experienced in 43% of patients. Botulinum toxin A for idiopathic overactive bladder is still under investigation.
- 1 : Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?: Preliminary results. J Urol2000; 164: 692. Link, Google Scholar
- 2 : Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol2004; 172: 240. Link, Google Scholar
- 3 : Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology2006; 68: 1193. Google Scholar
- 4 : Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology2004; 63: 868. Google Scholar
- 5 : Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol2007; 177: 2231. Link, Google Scholar
- 6 : Refractory urge urinary incontinence and botulinum a injection: the methods of the RUBI trial. J Appl Res2006; 6: 260. Google Scholar
- 7 : Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. Am J Obstet Gynecol2001; 185: 1388. Google Scholar
- 8 : A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol2001; 184: 552. Google Scholar
- 9 : Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol1994; 67: 1063. Google Scholar
- 10 : The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care1992; 30: 473. Google Scholar
- 11 : The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol2004; 172: 2316. Link, Google Scholar
- 12 : Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn2005; 24: 231. Google Scholar
- 13 : Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology2004; 63: 1071. Google Scholar
- 14 : European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol2004; 45: 510. Google Scholar
- 15 : Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology2005; 65: 37. Google Scholar
- 16 : Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol2006; 49: 644. Google Scholar
- 17 : Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol2006; 50: 684. Google Scholar
- 18 : A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol2005; 174: 984. Link, Google Scholar
- 19 : Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol2005; 48: 984. Google Scholar
- 20 : Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol2006; 49: 528. Google Scholar